David Shoultz leads our work in drug development. Photo: PATH.
Program Leader, Drug Development
David Shoultz, PhD, MS, MBA, directs PATH’s Drug Development program, which seeks to discover, develop, and deliver safe, effective, and affordable treatments for neglected diseases.
Prior to joining PATH in 2014, Dr. Shoultz served as the director of grantee and partner engagement and as a member of the leadership team at the Bill & Melinda Gates Foundation. In this role, he led an effort to strengthen the foundation’s relationships with its partner organizations to facilitate ongoing interactions and help achieve maximum impact. Previously, he served as a deputy director in the foundation’s Global Health Program, Infectious Disease, where he was central to strategy, planning, and management for four strategic program teams, including malaria, enteric diseases, pneumonia, and the neglected tropical diseases.
Prior to his roles at the foundation, Dr. Shoultz worked as a member of the senior management team for a number of clinical research organizations participating in the development of new medicines, including PPD Development, PRA International, and Biomedical Systems. He has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington since 2000 and sits on the board of the Geneva Foundation, where he also serves as the inaugural chair of the Scientific Advisory Committee.
Dr. Shoultz earned his PhD and MS from the School of Public Health and Community Medicine at the University of Washington, where he also obtained his BSN. He holds an MBA from the Albers School of Business and Economics at Seattle University, where he is a faculty member in the Executive MBA Program.